Approaching Climacteric Issues

  • Luciano de Melo Pompei
  • Nilson Roberto de Melo
  • César Eduardo Fernandes


The climacteric (perimenopause) causes clinical manifestations in the great majority of women, bringing serious damages to their quality of life. Hormone therapy (HT) is a very effective treatment for such manifestations; however, just like any treatments, it offers risks and benefits that must be carefully analyzed.

Recommended Reading

  1. 1.
    Baber RJ, Panay N, Fenton A. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–50.CrossRefGoogle Scholar
  2. 2.
    Kenemans P, Bundred N, Foidart JM, Kubista E, Schoultz B, Sismondi P, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol. 2009;10(2):135–46.CrossRefGoogle Scholar
  3. 3.
    North American Menopause Society. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728–53.CrossRefGoogle Scholar
  4. 4.
    Pompei LM, Brenelli FP, Araújo Neto JT, et al. Tratamento dos sintomas da menopausa na mulher de risco para câncer de mama. In: Associação de Obstetrícia e Ginecologia do Estado de São Paulo. Recomendações SOGESP, vol. 3. São Paulo; 2016. p. 215–28.Google Scholar
  5. 5.
    Wender MCO, Pompei LM, Fernandes CE. Consenso brasileiro de terapêutica hormonal da menopausa. Associação Brasileira de Climatério (SOBRAC). São Paulo: Leitura Médica; 2014.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Luciano de Melo Pompei
    • 1
  • Nilson Roberto de Melo
    • 2
  • César Eduardo Fernandes
    • 1
  1. 1.GynecologyABC Medical SchoolSanto AndreBrazil
  2. 2.GynecologyUniversity of São PauloSão PauloBrazil

Personalised recommendations